• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    PMGC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    4/17/26 7:31:18 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAB alert in real time by email
    false 0001840563 0001840563 2026-04-16 2026-04-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    Current Report

    PURSUANT TO SECTION 13 OR 15(d) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): April 16, 2026

     

    PMGC Holdings Inc.
    (Exact name of registrant as specified in its charter)

     

    Nevada   001-41875   33-2382547
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    c/o 120 Newport Center Drive

    Newport Beach, CA

      92660
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (888) 445-4886

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13©(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value   ELAB   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    Securities Purchase Agreement

     

    On April 16, 2026, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with a certain investor (“Investor”). The Purchase Agreement provides for an equity line of credit under which the Company agreed to issue and sell to Investor, upon the terms and conditions set forth in the Purchase Agreement those shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) issuable under pre-paid purchases (each, a “Pre-Paid Purchase”) in the aggregate purchase amount of up to $40,000,000 (such amount, the “Commitment Amount”), which includes the initial Pre-Paid Purchase to be made under the Purchase Agreement, upon the terms and subject to the limitations and conditions set forth in such Pre-Paid Purchase, as summarized herein: (i) an original principal amount of $10,730,000.00 (the “Pre-Paid Purchase Shares”); and (ii) an additional 262,467 shares of Common Stock (the “Registered Shares”).

     

    In connection with the Purchase Agreement, the Company also entered into the Pledge Agreement (as defined and described herein). Additionally, in connection with the Purchase Agreement, the Company’s current wholly-owned operating subsidiaries, Northstrive Biosciences Inc., a Delaware corporation (“Northstrive Biosciences”), PMGC Capital LLC, a Nevada limited liability company (“PMGC Capital”), AGA Precision Systems LLC, a California limited liability company (“AGA”), Pacific Sun Packaging Inc., a California corporation (“Pacific Sun”), and SVM Machining, Inc., a California corporation (“SVM”) each entered into a Guaranty (each, a “Guaranty”) for the benefit of Investor, as further described herein.

     

    Pre-Paid Purchase  

     

    The Pre-Paid Purchase carries an original issue discount of $700,000.00 (“OID”). The Company agreed to pay $30,000 to Investor to cover Investor’s legal fees, accounting costs, due diligence, and other transaction costs incurred in connection with the transactions contemplated by the Purchase Agreement (the “Transaction Expense Amount”). The Registered Shares and the Pre-Paid Purchase Shares shall be delivered on or around April 16, 2026 (the “Closing Date”). The initial purchase price payable to the Company on the Closing Date was $10,000,000, computed as follows: $10,730,000.00 initial principal balance, less the OID, less the Transaction Expense Amount. In addition, Investor also agreed to pay $1,000,000 to the Company for the Registered Shares.

     

    The Company expects to consummate the Pre-Paid Purchase on or about April 17, 2026 and to receive net proceeds of $9,727,380.00 after the deduction of the placement agent fee, legal fees, and other transaction-related expenses.

     

     1

     

     

    Request of Additional Pre-Paid Purchases

     

    Pursuant to the Purchase Agreement, the Company may, at its sole and absolute discretion, at any time and from time to time during the Commitment Period (as defined below), subject to the satisfaction of closing conditions, request a Pre-Paid Purchase in an amount no more than the Maximum Purchase Amount and no less than $250,000 from Investor by providing a written notice of such request to Investor (each, a “Request”). The closing of each Pre-Paid Purchase will take place on or before the third (3rd) Trading Day following the date of such Request (the date of the closing of each Pre-Paid Purchase, the “Pre-Paid Purchase Date”). Subject to the satisfaction of the conditions set forth in the Purchase Agreement as of such Pre-Paid Purchase Date, Investor shall pay to Company the amount set forth in such Request (which amount shall serve as the purchase price of such Pre-Paid Purchase) in immediately available funds to an account designated by Company in writing on each Pre-Paid Purchase Date immediately following delivery of the applicable fully executed Pre-Paid Purchase, except as noted in the Purchase Agreement. Each Pre-Paid Purchase will be considered a separate instrument with a separate outstanding balance and holding period. The original issue discount (“OID”) for each subsequent Pre-Paid Purchase will be seven percent (7.0%) of the amount set forth in the applicable Request, and each subsequent Pre-Paid Purchase will accrue interest at the rate of seven percent (7.0%) per annum. The floor price per share of Common Stock of each subsequent Pre-Paid Purchase will be twenty percent (20%) of the Nasdaq Minimum Price on the Pre-Paid Purchase Date, subject to another floor price for purposes of compliance with the Listing Rules of Nasdaq.

     

    “Commitment Period” means the period beginning on April 16, 2026 and ending on the earlier of: (i) April 16, 2028, (ii) the date the Company has sold $40,000,000.00 in Pre-Paid Purchases under the Purchase Agreement; and (iii) termination of the Purchase Agreement.

     

    Participation Right 

     

    The Company granted to Investor a participation right in which Investor has the right to participate, at Investor’s discretion and during the Commitment Period, in up to ten percent (10%) of the amount sold in any debt or equity financing (the “Participation Right”). Within two (2) Trading Days prior to the consummation of a financing (provided, however, that with respect to any public offering of the Company’s securities, the aforementioned time frame shall instead be upon the commencement of offers to the public), the Company will provide Investor with written notice of the consummation of such financing, along with copies of the transaction documents. Investor will then have up to five (5) Trading Days to elect to purchase up to ten percent (10%) of the amount of debt or equity securities issued in such transaction on the most favorable terms and conditions offered to any other purchaser of the same securities. The Company and Investor agreed that if the Company breaches its obligations with respect to the Participation Right, Investor’s sole and exclusive remedy is to receive liquidated damages.

     

    Weekly Sales Cap

     

    Investor agreed that, so long as no Event of Default has occurred under any Pre-Paid Purchase, it will not sell, during any calendar week, shares of Common Stock in an amount exceeding fifteen percent (15%) of the total weekly dollar trading volume of the Common Stock on all trading markets for such week.

     

    Covenants; Indemnification; Representations and Warranties

     

    The Company agreed that it shall not enter into any agreement or otherwise agree to any covenant, condition, or obligation that locks up, restricts in any way or otherwise prohibits Company: (i) from entering into a Variable Rate Transaction with Investor or any affiliate of Investor, or (ii) from issuing Common Stock, preferred stock, warrants, convertible notes, Pre-Paid Purchases, other debt securities, or any other Company securities to Investor or any affiliate of Investor, in each case without first obtaining the prior written consent of Investor, which may be granted or withheld in Investor’s sole and absolute discretion.

     

     2

     

     

    In addition, the Company agreed to file a Form 424(b)(5) prospectus supplement to on Form S-3 (Registration No. 333-284505) (“Shelf Registration Statement”) for the registration of the Registered Shares and that portion of the Pre-Paid Purchase Shares eligible for registration pursuant to General Instruction I.B.6 of Form S-3,.and deliver to Investor any legal opinions deemed necessary by Investor to trade the Registered Shares and the applicable portion of the Pre-Paid Purchase Shares under such prospectus supplement. The Company agreed to obtain stockholder approval of the issuance of the Registered Shares, the Pre-Paid Purchase Shares, all additional Pre-Paid Purchases that may be issued under the Purchase Agreement, and the shares of Common Stock issuable under such Pre-Paid Purchases in excess of the 19.99% issuance cap placed by Nasdaq Listing Rule 5635(d) and to file a Definitive Information Statement on Schedule 14C with the Securities & Exchange Commission to notify its stockholders of this approval.

     

    The Company agreed to reserve 7,500,000 shares of Common Stock from its authorized and unissued Common Stock to provide for all issuances of Common Stock under the Purchase Agreement and all Pre-Paid Purchases (the “Share Reserve”). The Company also further agreed to add additional Common Stock to the Share Reserve in increments of 100,000 shares of Common Stock as and when requested by Investor if as of the date of any such request the number of shares being held in the Share Reserve is less than three (3) times the number of Common Stock equal to the Pre-Paid Purchase Outstanding Balance divided by the Purchase Share Purchase Price.

     

    The Company and Investor agreed to other customary covenants, closing conditions, indemnification provisions and made customary representations and warranties.

     

    Termination

     

    The Company has the right to terminate the Purchase Agreement upon ten (10) days’ prior written notice to Investor so long as no Pre-Paid Purchases are outstanding.

     

    Guaranty; Pledge Agreement

     

    Northstrive Biosciences, PMGC Capital, AGA, Pacific Sun, and SVM each entered into the Guaranty for the benefit of Investor (each of these entities, in its capacity as a guaranty under the applicable Guaranty, collectively, the “Guarantors”). Pursuant to the Guaranty, the Guarantors agreed to absolutely and unconditionally guaranty the prompt payment in full of the Obligations.

     

    Pursuant to the Pledge Agreement, the Company’s obligations under the Pre-Paid Purchases and the other Transaction Documents are secured by: the Collateral, which includes the equity interests of the subsidiaries of the Company, any businesses purchased by the Company after the date of the Pledge Agreement, and the equity interests in any subsidiaries formed by the Company after the date of the Pledge Agreement. Investor has a first-position security interest in the Collateral.

     

    The Company agreed not to grant or create any security interest, claim, transfer restriction, lien, pledge or other encumbrance with respect to the Collateral or attempt to or actually sell, transfer or otherwise dispose of the Collateral, until the Obligations have been paid and performed in full.

     

    Capitalized terms used but not otherwise defined in this Current Report on Form 8-K shall have the respective meanings ascribed thereto by the Purchase Agreement, the Pre-Paid Purchase, the Guaranty, and the Pledge Agreement, as applicable. The foregoing summary of the Purchase Agreement, the First Pre-Paid Purchase, the Guaranty, and the Pledge Agreement and the transactions contemplated thereby do not purport to be complete and are subject to, and qualified in their entirety by, the full text of the Purchase Agreement, the First Pre-Paid Purchase, the Guaranty, and the Pledge Agreement, which are filed in this Current Report on Form 8-K as Exhibits 10.1, 10.2, 10.3, and 10.4, respectively.

     

     3

     

     

    Item 3.02 Unregistered Sales of Equity Securities.

     

    The disclosure required by this Item 3.02 and included in Item 1.01 of this Form 8-K is incorporated herein by reference. The sale of shares of Common Stock by the Company to the Investor pursuant to the Purchase Agreement, including both the Registered Shares and the Pre-Paid Purchase Shares were not registered under the Securities Act pursuant to the exemptions from registration available under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and/or Rule 506 of Regulation D promulgated thereunder.

     

    Item 7.01 Regulation FD Disclosure. 

     

    On April 17, 2026, the Company issued a press release, a copy of which is furnished as Exhibit 99.1 to this current report on Form 8-K.

     

    The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

     

    Item 9.01 Financial Statements and Exhibits.

     

    Exhibit No.   Description
    10.1+   Form of Securities Purchase Agreement
    10.2+   Form of Pre-Paid Purchase
    10.3+   Form of Guaranty
    10.4+   Form of Pledge Agreement
    99.1+   Press Release dated April 17, 2026
    104   Cover Page Interactive Data File (formatted in Inline XBRL).

     

    +Portions of this exhibit have been redacted.

     

     4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: April 17, 2026

     

    PMGC Holdings Inc.  
         
    By: /s/ Graydon Bensler  
    Name:  Graydon Bensler  
    Title: Chief Executive Officer and Chief Financial Officer  

     

     5

     

    Get the next $ELAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELAB
    SEC Filings

    View All

    SEC Form PRE 14C filed by PMGC Holdings Inc.

    PRE 14C - PMGC Holdings Inc. (0001840563) (Filer)

    4/17/26 7:32:11 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PMGC Holdings Inc. (0001840563) (Filer)

    4/17/26 7:31:18 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PMGC Holdings Inc. (0001840563) (Filer)

    4/9/26 7:40:45 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PMGC Holdings, Inc. (Nasdaq: ELAB) Secures $40 Million Equity Purchase Facility Agreement: Announces Ability To Accelerate M&A Strategy Currently Focused on Acquiring Aerospace and Defense Manufacturing Companies

    NEWPORT BEACH, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), a diversified holding company executing a targeted roll-up strategy in U.S.-based precision manufacturing, today announced its entry into a $40 million equity purchase facility (the "Facility") with an institutional investor. The initial tranche of approximately $10 million is expected to be funded at closing, anticipated today. The Company may draw additional amounts at its sole discretion over a 24-month commitment period and require the investor to purchase shares of common stock from the Company equal to the funded amounts and under subsequent pre-paid purchases, subjec

    4/17/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences

    NEWPORT BEACH, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. ("NorthStrive Biosciences"), a wholly owned subsidiary of PMGC Holdings Inc. ("PMGC" or the "Company") (NASDAQ:ELAB), today announced a key development milestone for its asset, EL-32: the successful transfer of the EL-32 Working Cell Bank ("WCB") to a U.S.-based third-party fermentation facility. This transfer initiates a manufacturing optimization program designed to increase production yield and establish a cost-efficient, scalable process in support of future clinical and commercial development. EL-32 is a dual-action engineered probiotic therapeutic designed to express both myostatin and activin-A a

    4/13/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacific Sun Packaging to Showcase Solutions at ITAD Europe 2026, Targeting Global Market Expansion

    NEWPORT BEACH, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Pacific Sun Packaging, Inc. ("Pacific Sun Packaging"), a packaging solutions provider specializing in custom-engineered packaging for the electronics and information technology (IT) hardware industries and a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC"), will be exhibiting at ITAD Europe 2026, the premier international conference for IT asset disposition (ITAD), reverse logistics, and circular electronics professionals. The Company's exhibition marks an expansion of its international presence as it engages with global buyers, recyclers, and enterprise decision-makers across the circular economy and e-waste man

    4/10/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: New insider Parry Jeffrey claimed ownership of 3 shares (SEC Form 3)

    3/A - PMGC Holdings Inc. (0001840563) (Issuer)

    2/10/26 9:43:04 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: New insider Daley Juliana claimed ownership of 1 shares (SEC Form 3)

    3/A - PMGC Holdings Inc. (0001840563) (Issuer)

    2/9/26 8:31:19 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Kovalyov George claimed no ownership of stock in the company (SEC Form 3)

    3 - PMGC Holdings Inc. (0001840563) (Issuer)

    1/29/26 8:08:05 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Leadership Updates

    Live Leadership Updates

    View All

    PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

    NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the "Company" or "PMGC," "our," or "we") (NASDAQ:ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group's ("TCA") Orange County network for 2025. As a Southern California Network Sponsor, PMGC is actively pursuing investments and M&A opportunities to strengthen its portfolio while fostering local business growth and expanding its market presence. TCA Venture Group (formerly known as Tech Coast Angels) is one of the largest and most active angel investor networks in the United States. With a history spanning over 25 years, TCA has been instrumental in funding early-s

    2/27/25 8:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

    Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, t

    7/30/24 9:00:26 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

    NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. "We are honored to be forming a Scientific Advisory Board with renowned members that possess deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical

    6/14/24 9:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    11/14/24 5:53:26 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    10/2/24 4:01:03 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    10/1/24 4:01:02 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Financials

    Live finance-specific insights

    View All

    NorthStrive Defense Tech Acquires Multi-Domain Drone Payload Technology Option for Defense and Commercial Applications

    NEWPORT BEACH, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- NorthStrive Defense Tech LLC ("NorthStrive Defense Tech"), a wholly-owned subsidiary of PMGC Holdings Inc. (the "Company") (NASDAQ:ELAB), today announced it has acquired rights to a novel drone technology through an exclusive option agreement ("Option Agreement") with a corporation. The Option Agreement provides NorthStrive Defense Tech with an exclusive option, within the aerospace and defense technologies field ("Field"), to get an exclusive license as to certain patent rights for U.S. Patent No. 12,291,334, covering a next-generation drone system designed to transport payloads across air and water environments. The option ("Opti

    4/6/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. Announces the Acquisition of SVM Machining, Inc.

    NEWPORT BEACH, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), a diversified public holding company announced that it has completed the acquisition of SVM Machining, Inc. ("SVM"). Founded in 1997 by Mark Serpa, SVM (aka Silicon Valley Manufacturing) is a Northern California-based ISO 9001:2015 Certified CNC precision machining and manufacturing services company serving medical, aerospace, biotech & pharmaceutical, semiconductor, and transportation markets. This transaction represents PMGC's third California based CNC machine shop acquisition to date, expanding PMGC's growing footprint in precision manufacturing and furthering its stra

    2/3/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. Completes Acquisition of CNC Machining Company - AGA Precision Systems LLC

    Adds $1.39 Million in Cash-Flow-Positive Revenue from a CNC Machining, Mold Manufacturing, and Specialty Metals Operation Serving the Aerospace, Defense, and Industrial Markets.Adds to PMGC's U.S. Manufacturing Revenue Through a Second Bolt-On Acquisition Under Its Roll-Up Strategy, Bringing Estimated Total Annualized Revenue to Over $2.25 Million. NEWPORT BEACH, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC" or "we"), a diversified public holding company, today announced that it has completed the acquisition of AGA Precision Systems LLC ("AGA"), a California-based CNC machining business that generated over $1.39 million in revenue in 2

    7/18/25 12:53:12 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care